[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336141-105":59,"doc-detail-336141-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","development-of-an-orally-bioavailable-mswisnf-atpase-degraderand-acquired-mechanisms-of-resistance-in-prostate-cancer","Development of an orally bioavailable mSWI/SNF ATPase degraderand acquired mechanisms of resistance in prostate cancer","","Development of AU-24118 focuses on an orally bioavailable PROTAC degrader that targets mSWI/SNF ATPases SMARCA2 and SMARCA4 and PBRM1 to impair enhancer-driven oncogenic transcription in prostate cancer. AU-24118 produces tumor regression in castration-resistant prostate cancer models, with improved effects when combined with enzalutamide. Preclinical studies in mice and rats show favorable pharmacokinetics and a supportive safety profile. Long-term exposure reveals resistance via SMARCA4 bromodomain mutations and ABCB1 overexpression, reversed by zosuquidar across tested degraders.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-an-orally-bioavailable-mswisnf-atpase-degraderand-acquired-mechanisms-of-resistance-in-prostate-cancer/336141/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-an-orally-bioavailable-mswisnf-atpase-degraderand-acquired-mechanisms-of-resistance-in-prostate-cancer/336141.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is AU-24118 and which targets does it degrade?","Question",{"text":113,"@type":114},"AU-24118 is an orally bioavailable PROTAC degrader. It targets mSWI/SNF ATPases SMARCA2 and SMARCA4 and PBRM1.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does AU-24118 perform in castration-resistant prostate cancer models?",{"text":118,"@type":114},"AU-24118 demonstrates tumor regression in castration-resistant prostate cancer models. The effect is further enhanced by combination with enzalutamide.",{"name":120,"@type":111,"acceptedAnswer":121},"What resistance mechanisms emerge after long-term treatment with mSWI/SNF PROTACs?",{"text":122,"@type":114},"Long-term exposure with high doses leads to SMARCA4 bromodomain mutations and ABCB1 overexpression. ABCB1 overexpression confers broader resistance to other PROTAC degraders, and the ABCB1 inhibitor zosuquidar reverses resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336141,1790151132,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nDevelopment of an orally bioavailable mSWI/SNF ATPase degraderand acquired mechanisms of resistance in prostate cancer  \nTongchen Hea, b,c,1, Caleb Chenga,d,e,1, Yuanyuan Qiaoa, b,f, Hanbyul Choa, b, Eleanor Younga, b, Rahul Mannana, b , Somnath Mahapatraa, b, Stephanie J. Minera, b , Yang Zhenga, b, NamHoon Kima, Victoria Z. Zenga, Jasmine P. Wisniewskia, Siyu Houg, Bailey Jacksona, Xuhong Caoa, b, h,  \nFengyun Sua, b, Rui Wanga, b , Yu Changa, b, Bilash Kuilai, Subhendu Mukherjeei, Sandeep Dukarei, Kiran B. Aithali, Samiulla D. S. i, Chandrasekhar Abbinenii, Ulka Vaishampayanf,j, Costas A. Lyssiotisf, k, l, Abhijit Paroliaa, b,f, Lanbo Xiaoa, b,f,2, and Arul M. Chinnaiyana, b,f, h, m,2  \nContributed by Arul M. Chinnaiyan; received December 21, 2023; accepted March 2, 2024; reviewed by Ronald A. DePinho and Matthew G. Oser  \nMammalian switch/sucrose nonfermentable (mSWI/SNF) ATPase degraders have been shown to be effective in enhancer-driven cancers by functioning to impede oncogenic transcription factor chromatin accessibility. Here, we developed AU-24118, an orally bioavailable proteolysis-targeting chimera (PROTAC) degrader ofmSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1. AU-24118 demonstrated tumor regression in a model of castration-resistant prostate cancer (CRPC) which was further enhanced with combination enzalutamide treatment, a standard of care androgen receptor (AR) antagonist used in CRPC patients. Importantly, AU-24118 exhibited favorable pharmacokinetic profiles in preclinical analyses in mice and rats, and further toxicity testing in mice showed a favorable safety profile. As acquired resistance is common with targeted cancer therapeutics, experiments were designed to explore potential mechanisms of resistance that may arise with long-term mSWI/SNF ATPase PROTAC treatment. Prostate cancer cell lines exposed to long-term treatment with high doses ofa mSWI/SNF ATPase degrader developed SMARCA4 bromodomain mutations and ABCB1 (ATP binding cassette subfamily B member 1) overexpression as acquired mechanisms of resistance. Intriguingly, while SMARCA4 mutations provided specific resistance to mSWI/SNF degraders, ABCB1 overexpression provided broader resistance to other potent PROTAC degraders targeting bromodomain-containing protein 4 andAR. The ABCB1 inhibitor, zosuquidar, reversed resistance to all three PROTAC degraders tested. Combined, these findings position mSWI/SNF degraders for clinical translation for patients with enhancer-driven cancersand define strategies to overcome resistance mechanisms that may arise.  \nmSWI/SNF | SMARCA2 | SMARCA4 | proteolysis-targeting chimera (PROTAC) | ABCB1  \nEpigenetic dysregulation has recently emerged as a promising avenue for innovative therapeutic approaches in the treatment of human cancer (1, 2). The mammalian switch/sucrose nonfermentable (mSWI/SNF) complex, a key player in this realm, exerts its influence on chromatin topology and gene expression by orchestrating the movement of nucleosome substrates (3). Comprising 11 to 15 subunits organized into canonical BRG1/BRM-associated factor (cBAF), polybromo-associated BAF (pBAF), and noncanonical BAF forms (ncBAF), the complex is fueled by two ATPases, SMARCA2 and SMARCA4, which hydrolyze adenosine triphosphate (ATP) to power the mSWI/SNF complexes (4–8) . Recent research has underscored the potential of targeting these ATPase components, as perturbing them has been shown to impede tumor maintenance and oncogenicity (9–12) . Notably, multiple small molecule compounds specifically targeting ATPase mSWI/SNF subunits have been developed, with ongoing clinical trials (NCT04879017, NCT04891757) evaluating SMARCA2/4-targeting small molecules (13–16) .  \nConcurrently, the field of cancer treatment research has witnessed a surge in interest in proteolysis-targeting chimera (PROTAC) technology (17, 18) . Several drugs based on PROTAC degraders are undergoing clinical trials, s","cbCainf064rf4RDb","https://ap.wps.com/l/cbCainf064rf4RDb","pdf",2433389,11,"English","# Significance\n## Key findings and resistance mechanisms","[{\"question\":\"What is AU-24118 and which targets does it degrade?\",\"answer\":\"AU-24118 is an orally bioavailable PROTAC degrader. It targets mSWI/SNF ATPases SMARCA2 and SMARCA4 and PBRM1.\"},{\"question\":\"How does AU-24118 perform in castration-resistant prostate cancer models?\",\"answer\":\"AU-24118 demonstrates tumor regression in castration-resistant prostate cancer models. The effect is further enhanced by combination with enzalutamide.\"},{\"question\":\"What resistance mechanisms emerge after long-term treatment with mSWI/SNF PROTACs?\",\"answer\":\"Long-term exposure with high doses leads to SMARCA4 bromodomain mutations and ABCB1 overexpression. ABCB1 overexpression confers broader resistance to other PROTAC degraders, and the ABCB1 inhibitor zosuquidar reverses resistance.\"}]","Development of an orally bioavailable mSWI/SNF ATPase degraderand acquired mechanisms of resistance in prostate cancer | PDF",1790013783,28]